Compare FMC Corp (FMC) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FMC Corp vs ResMed Inc. — how do they compare? FMC Corp trades at $8.35 (market cap $1.39B), while ResMed Inc. trades at $230.05 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 22.9× FMC Corp's market cap, and FMC Corp pays the higher dividend (3.59%). Which is the better fit depends on your goals — on Pluang, investors hold FMC Corp for 68 Days and ResMed Inc. for 51 Days on average.
| FMC | RMD | |
|---|---|---|
Market Cap | $1.39B | $31.89B |
Volume | 4,145,979 | 618,314 |
Sector | Basic Materials | Health |
52-Week High | $30.63 | $275.96 |
52-Week Low | $8.35 | $182.82 |
Typical Hold Time | 68 Days | 51 Days |
Enterprise Value | $5.19B | $31.24B |
Dividend Yield | 3.59% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FMC trades at $8.92, down 1.87% on the day, with a bearish technical outlook and mixed fundamentals. The stock shows weak profitability with a net income margin of -84.83% and negative ROE of -91.47% for 2025, though recent quarterly EPS beats offer some optimism. Analyst consensus is divided with a near-even split between Buy and Hold ratings, and a $14.60 price target suggests significant upside from current levels. Recent news highlights regulatory progress for rimisoxafen in Brazil and a minority equity investment from Tessenderlo Group.
The outlook for FMC hinges on successful deleveraging and product approvals, but high debt and cyclical industry pressures pose substantial risks. While valuation ratios like P/S of 0.34 appear attractive, persistent negative margins and volatile cash flows warrant caution. The stock presents a speculative opportunity for investors betting on a turnaround, but near-term headwinds in the agricultural sector may limit upside.
ResMed (RMD) trades at $226.73, up 0.33% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming earnings report and positive analyst commentary on growth prospects.
The outlook is positive, driven by consistent earnings outperformance and a consensus price target of $242.70, implying upside. Key risks include competitive pressures and ongoing legal investigations. Institutional interest remains strong, with recent stake increases by funds. The stock's valuation metrics, such as a P/E of 21.74, appear reasonable given growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
